Enveric Biosciences, Inc. (ENVB), a biotechnology firm, announced on Monday that it has successfully completed preclinical pharmacokinetic studies in both rats and dogs. These studies reinforce the oral bioavailability and targeted non-hallucinogenic characteristics of EB-003.
The company highlighted substantial brain penetration in the rat model, exhibiting a brain-to-plasma ratio of approximately 5-6. This is notably higher compared to the mouse model, which showed a ratio of about 1.5.
Importantly, no clinical signs or indications of hallucination were observed in either study. EB-003 is being developed to address challenging mental health disorders.
The research demonstrated the potential to leverage neuroplastic properties without inducing hallucinations. Enveric Biosciences plans to submit an Investigational New Drug (IND) application to the FDA in the latter half of 2025.
